In addition, several potentially key effectors of prostate cancer cell proliferation were identified in the BPA-treated cohort, including FIGF (c-fos–induced growth factor, also called VEGF-D; UniGene ID Hs.11392), which has been associated with advanced-stage metastatic prostate cancer (Kaushal et al. 2005). Here, VEGFD is linked to prostate carcinoma.